🔴 TRIAL shows PFIZER'S COVID antiviral PILLslashes hospitalisation RISK

 

 INTERNACIONAL  Pfizer’s Covid-19 oral antiviral drug cut the risk of hospitalisation or death by 89 per cent in a late-stage trial, creating a potential new tool in treating patients and combating the pandemic.The US pharmaceutical company said on Friday that it was stopping the trial due to the “overwhelming efficacy” and will add the data for the drug known as Paxlovid to its rolling submission to the US Food and Drug Administration for an emergency use authorisation as soon as possible.